Form 4: Werewolf Therapeutics Director Sells Shares

Luke Evnin, a director at Werewolf Therapeutics, Inc., reported the sale of 125,576 shares of common stock through pre-arranged 10b5-1 plans.

Summary

• Director Luke Evnin reported multiple sales of Werewolf Therapeutics, Inc. common stock.
• Transactions occurred on November 21, 2025, November 24, 2025, and November 25, 2025.
• A total of 125,576 shares were sold across these dates.
• The sales were executed under a Rule 10b5-1 trading plan established on September 24, 2025.
• The shares were sold at weighted average prices ranging from $0.83 to $0.98 per share.
• Following these transactions, Evnin's indirect beneficial ownership stands at 3,287,551 shares.

Sentiment

Score: 4

Explanation: The sentiment is mildly negative due to insider selling, but mitigated by the fact that the sales were pre-planned under a 10b5-1 plan, reducing the implication of immediate negative news. The low share price at which sales occurred is a minor concern.

Positives

• The sales were conducted under a pre-established Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to new, negative information.

Negatives

• A director's sale of a significant number of shares could be perceived negatively by the market, potentially signaling a lack of confidence or a need for liquidity.
• The sales occurred at prices below $1.00 per share, which might reflect a low valuation for the company's stock.

Risks

• Potential negative market perception due to insider selling, which could put downward pressure on the stock price.
• The company's stock trading at prices below $1.00 per share could indicate underlying business challenges or market disinterest.

Future Outlook

NA

Management Comments

• The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Industry Context

This filing reflects an individual director's stock transactions and does not provide broader industry context. However, insider selling, even if pre-planned, can sometimes be interpreted by the market in the context of the company's specific sector performance or general market sentiment towards biotechnology stocks.

Related Party Transactions

• The shares are indirectly held by various MPM entities (MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P.). Luke Evnin is a member, managing director, or manager of these entities, establishing a related party relationship for the beneficial ownership.

Stakeholder Impact

• Shareholders: May interpret the insider sales as a negative signal, potentially leading to downward pressure on the stock price. However, the 10b5-1 plan mitigates the severity of this interpretation.
• Employees, Customers, Suppliers, Creditors: Unlikely to be directly impacted by this specific insider transaction report.

Key Dates

Recommendation

While insider selling can be a negative signal, these transactions were executed under a pre-established 10b5-1 plan, suggesting they are not based on new, undisclosed negative information. The director still retains a significant indirect stake. Given the context of a planned divestment and the existing indirect ownership, a 'hold' recommendation is appropriate, advising investors to monitor future company performance and broader market trends rather than reacting solely to these planned sales.

Keywords

Werewolf Therapeutics, HOWL, Luke Evnin, Insider Selling, Form 4, SEC Filing, Stock Sale, 10b5-1 Plan, Biotechnology, Director Transaction